Prostate tumor progression and prognosis: Interplay of tumor and host factors

Urologic Oncology

Volumn 5, Issue 6, 2000, Pages 258-264

  Harding, Michael A ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Biological tumor markers; Molecular cloning; Prognosis; Prostate neoplasms

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CHROMOGRANIN A; CYTOKINE; INTERLEUKIN 8; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; HUMAN; MALE; MALE GENITAL TRACT TUMOR; METASTASIS; MOLECULAR CLONING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0033801992     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00073-9     Document Type: Review

References (60)

1. Fidler I.J. Cancer metastasis. Br Med Bull. 47:1991;157-177.
2. Fidler I.J. Critical determinants of cancer metastasis. rationale for therapy Cancer Chemother Pharmacol. 43:1999;S3-10.
3. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
4. Polascik T.J., Pound C.R., DeWeese T.L., Walsh P.C. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer. a 7-year biochemical (PSA) progression analysis Urology. 51:1998;884-890.
5. Forman J.D., Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology. 12:1998;33-47.
6. Harding M.A., Theodorescu D. Prognostic markers in localized prostate cancer. from microscopes to molecules Cancer Metastasis Rev. 17:1998;429-437.
7. Sakr W.A., Grignon D.J. Prostate cancer. indicators of aggressiveness Eur Urol. 32:1997;15-23.
8. Gao X., Porter A.T., Grignon D.J., Pontes J.E., Honn K.V. Diagnostic and prognostic markers for human prostate cancer. Prostate. 31:1997;264-281.
9. Reference deleted in proof.
10. Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17:222-72.
11. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
12. Nowell P.C. Mechanisms of tumor progression. Cancer Res. 46:1986;2203-2207.
13. Theodorescu D., Cornil I., Sheehan C., Man S., Kerbel R.S. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer. 47:1991;118-123.
14. Theodorescu D., Caltabiano M., Greig R., Rieman D., Kerbel R.S. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo. J Cell Physiol. 148:1991;380-390.
15. Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 39:1999;135-148.
16. Cussenot O., Villette J.M., Cochand-Priollet B., Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate. Suppl 8:1998;43-51.
17. Theodorescu D., Broder S.R., Boyd J.C., Mills S.E., Frierson H.F. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 80:1997;2109-2119.
18. Abrahamsson P.A., Cockett A.T., di Sant'Agnese P.A. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate. Suppl. 8:1998;37-42.
19. Weinstein M.H., Partin A.W., Veltri R.W., Epstein J.I. Neuroendocrine differentiation in prostate cancer. enhanced prediction of progression after radical prostatectomy Hum Pathol. 27:1996;683-687.
20. Harper M.E., Glynne-Jones E., Goddard L., Thurston V.J., Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer. 74:1996;910-916.
21. Cox M.E., Deeble P.D., Lakhani S., Parsons S.J. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible. implications for prostate cancer progression Cancer Res. 59:1999;3821-3830.
22. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 136:1972;261-276.
23. Mahadevan V., Hart I.R. Metastasis and angiogenesis. Acta Oncol. 29:1990;97-103.
24. Volpert O.V., Dameron K.M., Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 14:1997;1495-1502.
25. Shurbaji M.S., Kalbfleisch J.H., Thurmond T.S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 26:1995;106-109.
26. Kvanta A., Steen B., Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 63:1996;511-518.
27. Bostwick D.G., Wheeler T.M., Blute M., Barrett D.M., MacLennan G.T., Sebo T.J., Scardino P.T., Humphrey P.A., Hudson M.A., Fradet Y., Miller G.J., Crawford E.D., Blumenstein B.A., Mahran H.E., Miles B.J. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 48:1996;47-57.
28. Vartanian R.K., Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia. correlation with Gleason's score, microvessel density, and epithelial cell proliferation Lab Invest. 73:1995;844-850.
29. Brawer M.K., Deering R.E., Brown M., Preston S.D., Bigler S.A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 73:1994;678-687.
30. Theodorescu D., Broder S.R., Boyd J.C., Mills S.E., Frierson H.F. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 158:1997;131-137.
31. Krupski T., Petroni G.R., Frierson H.F., Theodorescu D. Microvessel density, p53, retinoblastoma, and chromogranin a immunohistochemistry as predictors of disease-specific survivial following radical prostatectomy for carcinoma of the prostate. Urology. 55:2000;743-749.
32. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:1998;715-725.
33. Jain R.K., Schlenger K., Hockel M., Yuan F. Quantitative angiogenesis assays. progress and problems Nat Med. 3:1997;1203-1208.
34. Gazit Y., Baish J.W., Safabakhsh N., Leunig M., Baxter L.T., Jain R.K. Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation. 4:1997;395-402.
35. Baish J.W., Gazit Y., Berk D.A., Nozue M., Baxter L.T., Jain R.K. Role of tumor vascular architecture in nutrient and drug delivery. an invasion percolation-based network model Microvasc Res. 51:1996;327-346.
36. Dachs G.U., Patterson A.V., Firth J.D., Ratcliffe P.J., Townsend K.M., Stratford I.J., Harris A.L. Targeting gene expression to hypoxic tumor cells. Nat Med. 3:1997;515-520.
37. Miller G.J., Cygan J.M. Morphology of prostate cancer. the effects of multifocality on histological grade, tumor volume and capsule penetration J Urol. 152:1994;1709-1713.
38. Greene D.R., Wheeler T.M. Clinical relevance of the individual prostate cancer focus. Cancer Invest. 12:1994;425-437.
39. Villers A., McNeal J.E., Freiha F.S., Stamey T.A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer. 70:1992;2313-2318.
40. Ruijter E.T., van de Kaa C.A., Schalken J.A., Debruyne F.M., Ruiter D.J. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 180:1996;295-299.
41. Macintosh C.A., Stower M., Reid N., Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res. 58:1998;23-28.
42. Bostwick D.G., Shan A., Qian J., Darson M., Maihle N.J., Jenkins R.B., Cheng L. Independent origin of multiple foci of prostatic intraepithelial neoplasia. comparison with matched foci of prostate carcinoma Cancer. 83:1998;1995-2002.
43. Zitzelsberger H., Kulka U., Lehmann L., Walch A., Smida J., Aubele M., Lorch T., Hofler H., Bauchinger M., Werner M. Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virchows Arch. 433:1998;297-304.
44. Emmert-Buck M.R., Vocke C.D., Pozzatti R.O., Duray P.H., Jennings S.B., Florence C.D., Zhuang Z., Bostwick D.G., Liotta L.A., Linehan W.M. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 55:1995;2959-2962.
45. Ozen M., Hopwood V.L., Johnston D.A., Babaian R.J., Logothetis C.J., von Eschenbach A.C., Pathak S. Aneuploidy index in blood. a potential marker for early onset, androgen response, and metastasis in human prostate cancer Urology. 53:1999;381-385.
46. Ozen M., Multani A.S., Kuniyasu H., Chung L.W., von Eschenbach A.C., Pathak S. Specific histologic and cytogenetic evidence for in vivo malignant transformation of murine host cells by three human prostate cancer cell lines. Oncol Res. 9:1997;433-438.
47. Hayward S.W., Grossfeld G.D., Tlsty T.D., Cunha G.R. Genetic and epigenetic influences in prostatic carcinogenesis. Int J Oncol. 13:1998;35-47. [review].
48. Chung L.W. The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv. 23:1995;33-42.
49. Gleave M., Hsieh J.T., Gao C.A., von Eschenbach A.C., Chung L.W. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51:1991;3753-3761.
50. Merz V.W., Miller G.J., Krebs T., Timme T.L., Kadmon D., Park S.H., Egawa S., Scardino P.T., Thompson T.C. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate. evidence for a paracrine role during progression Mol Endocrinol. 5:1991;503-513.
51. Thompson T.C., Southgate J., Kitchener G., Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell. 56:1989;917-930.
52. Thompson T.C., Timme T.L., Kadmon D., Park S.H., Egawa S., Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog. 7:1993;165-179.
53. van Weerden W.M., de Ridder C.M., Verdaasdonk C.L., Romijn J.C., van der Kwast T.H., Schroder F.H., van Steenbrugge G.J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol. 149:1996;1055-1062.
54. Wood D.P., Banks E.R., Humphreys S., McRoberts J.W., Rangnekar V.M. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer. 74:1994;2533-2540.
55. Deguchi T., Yang M., Ehara H., Ito S., Nishino Y., Takahashi Y., Ito Y., Shimokawa K., Tanaka T., Imaeda T., Doi T., Kawada Y. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer. 75:1997;634-638.
56. Gao C.L., Dean R.C., Pinto A., Mooneyhan R., Connelly R.R., McLeod D.G., Srivastava S., Moul J.W. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol. 161:1999;1070-1076.
57. Cher M.L., de Oliveira J.G., Beaman A.A., Nemeth J.A., Hussain M., Wood D.P. Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res. 5:1999;2421-2425.
58. Jacob K., Webber M., Benayahu D., Kleinman H.K. Osteonectin promotes prostate cancer cell migration and invasion. a possible mechanism for metastasis to bone Cancer Res. 59:1999;4453-4457.
59. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W. Osteopontin. possible role in prostate cancer progression Clin Cancer Res. 5:1999;2271-2277.
60. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 54:1999;523-527.